#United States #Las Vegas #Concept Medical #MagicTouch PTA #SirPAD Study

Overview of the SirPAD Study

The SirPAD randomized trial, a groundbreaking study in the treatment of patients with femoropopliteal peripheral artery disease (PAD) causing intermittent claudication, will present its latest findings at the VIVA 2026 conference. Taking place from October 3 to 6 in Las Vegas, the study focuses on the efficacy of the MagicTouch sirolimus-coated balloon by Concept Medical compared to uncoated balloons in angioplasty procedures.

Study Details

A total of 1,252 patients diagnosed with symptomatic infrainguinal PAD were enrolled in this significant trial. Participants underwent angioplasty procedures using either the sirolimus-coated balloon or the uncoated alternative to determine the most effective method in reducing major adverse limb events (MALE) after one year. The main findings, recently published in the prestigious New England Journal of Medicine, showcased a remarkable decrease in adverse outcomes for patients treated with the MagicTouch balloon.

In this upcoming presentation, the focus will narrow to a subset of 597 patients specifically suffering from femoropopliteal disease without tissue loss. This group's treatment objectives extend beyond simple limb preservation; they are also aimed at achieving long-lasting relief from symptoms, a significant consideration in patient care.

Key Presentation at VIVA 2026

Professor Dr. Stefano Barco, co-principal investigator of the trial, will share these latest insights as part of the late-breaking clinical trial program at VIVA 2026. This international meeting is renowned for addressing issues related to peripheral vascular disease and advanced endovascular therapies, making it the perfect platform for these crucial updates. The information presented could substantially influence treatment protocols and patient outcomes in the future.

Understanding the SirPAD Trial

The SirPAD trial stands as a prominent example of academic-driven research aimed at enhancing treatment methodologies for patients suffering from femoropopliteal or below-the-knee diseases. Since its inception, the study has compared the outcomes related to the use of the sirolimus-coated balloon—MagicTouch PTA—against traditional uncoated balloon treatments. The trial's primary outcomes have already established that the sirolimus-treated group not only demonstrated non-inferiority but also superiority concerning MALE compared to those receiving the uncoated balloon.

About Concept Medical

Concept Medical is at the forefront of developing pioneering drug-delivery technologies aimed at improving coronary and peripheral vascular interventions. The MagicTouch PTA is a notable advancement in this field and was specifically evaluated in the randomized SirPAD trial. Their commitment to innovation helps redefine treatment standards for PAD and similar vascular conditions, positioning the company as a leader in the medical device sector.

For those interested in reviewing more about Concept Medical and their innovative approaches, additional details are available on their official website at www.conceptmedical.com.

Conclusion

As the SirPAD findings prepare to be unveiled at VIVA 2026, the potential implications for patient care and clinical practices are profound. With an emphasis on achieving not only limb preservation but also sustaining symptom relief, the SirPAD trial could redefine therapeutic paths for patients suffering from femoropopliteal PAD, elevating standards of care in the domain.